Madhavan Balachandran

Madhavan Balachandran filed 49 reports from February 1, 2016 to June 26, 2026, across four companies: uniQure N.V. (26 filings, Director), Amgen Inc (13, EVP, Operations), Catalent, Inc. (8, Director) and Stevanato Group S.p.A. (2, Director). Fifteen sales make up the market trades, worth EUR 5.0 million in total, but with a median of EUR 39,441: one trade carries most of it, EUR 4,022,948 on May 4, 2016 at Amgen. The next two, EUR 240,206 on June 15, 2026 and EUR 216,634 on June 17, 2026, are at uniQure. No purchase.

The record also holds 25 grants, 6 filings of another nature and 3 option exercises. The year 2016 has 13 filings, then the pace falls to 1 in 2017 and rises again to 11 in 2026. The last twelve months hold 11, 6 of them sales.

Publication takes a median of 4 days. At uniQure, 10 of Balachandran's trades fall within 30 days of a trade by Matthew C. Kapusta, 8 of Jack Kaye, 8 of Jeremy P. Springhorn, 7 of Christian Klemt and 7 of David D. Meek, all in the same direction.